Roseburia intestinalis (R. intestinalis) and Faecalibacterium prausnitzii are found to be the bacteria that produced butyrate most in human faeces. Butyrate has been reported to exert pervasive anti-inflammatory and metabolic modulation effects in different disease models. Therefore, R. intestinalis can be applied as a potential probiotic. Creative Biolabs is a premier live biotherapeutic products (LBP) development contract provider in the United States. Our experience and expertise are at your service.
R. intestinalis is an anaerobic, Gram-positive, slightly curved rod-shaped flagellated bacterium that produces butyrate in the colon. that was first isolated from human feces. It belongs to the Roseburia genus in Clostridium cluster XIVa of the Firmicutes phylum, which is essential for host metabolism. It was reported that R. intestinalis XB6B4 can be cultivated under anaerobic conditions at 37℃ in a complex medium containing clarified rumen fluid and 0%-5% complex substrates. Evidence suggests that this bacterium contributes to a variety of diseases, such as inflammatory bowel disease, type 2 diabetes, antiphospholipid syndrome, and atherosclerosis.
Based on the clinical data showing that populations of R. intestinalis are dramatically decreased in the gut of patients with ulcerative colitis, scientists studied the efficacy of a strain belonging to this species in the context of colitis and stress using animal models. Colitis-related symptoms in rats were significantly relieved after R. intestinalis enema, and the stool traits and colon length of rats were significantly recovered after treatment. The administration of R. intestinalis contributes to restoration of the gut microbiota, promoting colon repair and the recovery of gastrointestinal function. These findings suggest the therapeutic and protective effects of R. intestinalis on UC.
Fig.1 R. intestinalis modulation in the colonic tract. (Nie, 2021)
Metabolic diseases are typically multi-nutrition utilizing disorders and abnormalities of immune-induced hormones. Butyrate can increase energy expenditure and lipid oxidation, which affects energy homeostasis and lipid metabolism. To date, there is strong evidence of a link between R. intestinalis and type 2 diabetes mellitus (T2DM). A metagenomic-wide association study (MGWAS) based on deep shotgun sequencing of the gut microbiota DNA from 345 Chinese individuals in a large population found that the abundance of R. intestinalis decreased in T2DM patients. These studies suggest that R. intestinalis plays a broad supporting role in metabolic disorders. Perhaps, R. intestinalis will be included in mixed probiotic prescriptions for metabolic disorders in the future.
Fig. 2 Different therapeutic methods targeting R. intestinalis in potential diseases. (Nie, 2021)
We supply a variety of R. intestinalis strains as below. If you need other strains, please contact us.
As an important butyrate producer, R. intestinalis has broad application prospects in the development of new probiotics. It is expected that the treatment of intestinal R. intestinalis will significantly improve the specific human pathogenic state. If you are interested in R. intestinalis related products or services, Creative Biolabs is happy to discuss your objectives. You can count on our skilled and passionate workforce to find the most suitable path. Please feel free to contact us to start today.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.